- Home
- YYAI vs MBRX Comparison
YYAI vs MBRX Comparison
Compare YYAI & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YYAI
- MBRX
- Stock Information
- Founded
- YYAI 2015
- MBRX 2015
- Country
- YYAI Hong Kong
- MBRX United States
- Employees
- YYAI N/A
- MBRX N/A
- Industry
- YYAI
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- YYAI
- MBRX Health Care
- Exchange
- YYAI NYSE
- MBRX Nasdaq
- Market Cap
- YYAI 13.7M
- MBRX 12.9M
- IPO Year
- YYAI N/A
- MBRX 2016
- Fundamental
- Price
- YYAI $0.89
- MBRX $0.31
- Analyst Decision
- YYAI
- MBRX Strong Buy
- Analyst Count
- YYAI 0
- MBRX 3
- Target Price
- YYAI N/A
- MBRX $5.33
- AVG Volume (30 Days)
- YYAI 186.5K
- MBRX 5.2M
- Earning Date
- YYAI 08-05-2025
- MBRX 08-13-2025
- Dividend Yield
- YYAI N/A
- MBRX N/A
- EPS Growth
- YYAI N/A
- MBRX N/A
- EPS
- YYAI N/A
- MBRX N/A
- Revenue
- YYAI N/A
- MBRX N/A
- Revenue This Year
- YYAI N/A
- MBRX N/A
- Revenue Next Year
- YYAI N/A
- MBRX N/A
- P/E Ratio
- YYAI N/A
- MBRX N/A
- Revenue Growth
- YYAI N/A
- MBRX N/A
- 52 Week Low
- YYAI $0.35
- MBRX $0.25
- 52 Week High
- YYAI $18.96
- MBRX $4.71
- Technical
- Relative Strength Index (RSI)
- YYAI 51.78
- MBRX 24.39
- Support Level
- YYAI $0.75
- MBRX $0.25
- Resistance Level
- YYAI $0.92
- MBRX $0.42
- Average True Range (ATR)
- YYAI 0.11
- MBRX 0.06
- MACD
- YYAI -0.00
- MBRX -0.03
- Stochastic Oscillator
- YYAI 33.33
- MBRX 13.07
About YYAI CONNEXA SPORTS TECHNOLOGIES IN
Connexa Sports Technologies Inc operates in the sports equipment and technology business. It is a connected sports company delivering products, technologies, and services across the Watch, Play, Learn commercial and subscription-as-a-service activities in sports. The company's offerings include Slinger Launcher, which is comprised of a portable tennis ball launcher, a portable padel tennis ball launcher, and a portable pickleball launcher. Through Gameface, it provides AI technology and performance analytics.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.